PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product ...

JPMorgan analyst Eric Joseph lowered the firm’s price target on PTC Therapeutics (PTCT) to $72 from $74 and keeps an Overweight rating on the ...

PTC Therapeutics Inc (NASDAQ:PTCT) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price target of ...

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $65.9 million in its fourth quarter. The Warren, New Jersey-based company said it had a loss of 85 ...

Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Learn more about whether PTC Therapeutics, Inc. or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Full year 2024 revenue of $807 million, exceeding guidance - - All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been given an average rating of “Hold” by the fifteen research firms that are presently covering the company ...